<DOC>
	<DOCNO>NCT00032032</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose radiation therapy give combination chemotherapy see well work treat patient non-small cell lung cancer surgically remove .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose radiotherapy combination carboplatin paclitaxel patient unresectable non-small cell lung cancer . - Determine 2-year survival patient treat regimen . - Determine progression-free local control rate patient treat regimen . - Determine tolerability regimen patient . - Assess quality life patient treat regimen . OUTLINE : This multicenter , dose-escalation study radiotherapy . Patients undergo radiotherapy* daily 5 day week 7 week 2 day ( total 37 fraction ) . Patients concurrently receive paclitaxel IV 3 hour carboplatin IV 30 minute weekly 7 week . Treatment continue absence disease progression unacceptable toxicity . NOTE : *No prophylactic nodal radiotherapy administer Cohorts 3-6 patient receive escalate dos radiotherapy maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 12 additional patient treat dose level phase II portion study . Beginning 3 week completion radiotherapy , patient receive paclitaxel carboplatin . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Quality life assess baseline , last week radiotherapy , every 3 month 2 year . Patients follow 3 week , every 3 month 21 month , every 6 month 3 year . PROJECTED ACCRUAL : A total 90 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage I , II , III NSCLC unresectable due tumor extent medical reason Measurable disease Tumor must exceed volume would require radiation volume great allow study No blunting costophrenic angle chest xray due pleural effusion No small effusion see chest CT scan No supraclavicular adenopathy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Total bilirubin great 1.5 time upper limit normal ( ULN ) OR Direct bilirubin great 1.5 time ULN AST great 3 time ULN Renal : Creatinine clearance least 40 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Pulmonary : FEV_1 least 1 L 35 % predict Other : No grade 2 great peripheral neuropathy No weight loss 10 % within past 3 month No uncontrolled infection No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , adequately treat noninvasive carcinoma ( carcinoma situ ) , localized prostate cancer No severe underlie disease would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic : No prior biologic therapy NSCLC No concurrent biologic therapy No concurrent prophylactic filgrastim ( GCSF ) Chemotherapy : No prior chemotherapy NSCLC No concurrent chemotherapy Endocrine therapy : No prior endocrine therapy NSCLC Radiotherapy : No prior radiotherapy NSCLC Surgery : No prior surgery NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>